Q3 · MEDICINE
Article
Author: Orr, Christine J. ; Sneeringer, Christopher J. ; Shanahan, Frances ; La, Hank ; Leung, Dennis H. ; Wang, Weiru ; Yin, Jianping ; Muli, Christine S. ; Durk, Matthew R. ; Liu, Wendy ; Rudolph, Joachim ; Gibbons, Paul ; Huestis, Malcolm P. ; Siu, Michael ; Merchant, Mark ; Yen, Ivana ; Parr, Brendan T. ; Hunsaker, Thomas L. ; Malek, Shiva ; Eigenbrot, Charles ; Moffat, John G.
Structure-based optimization of a set of aryl urea RAF inhibitors has led to the identification of Type II pan-RAF inhibitor GNE-9815 (7), which features a unique pyrido[2,3-d]pyridazin-8(7H)-one hinge-binding motif. With minimal polar hinge contacts, the pyridopyridazinone hinge binder moiety affords exquisite kinase selectivity in a lipophilic efficient manner. The improved physicochemical properties of GNE-9815 provided a path for oral dosing without enabling formulations. In vivo evaluation of GNE-9815 in combination with the MEK inhibitor cobimetinib demonstrated synergistic MAPK pathway modulation in an HCT116 xenograft mouse model. To the best of our knowledge, GNE-9815 is among the most highly kinase-selective RAF inhibitors reported to date.